Bifogade filer
Kurs
+1,86%
Kalender
Tid* | ||
2026-02-03 | N/A | Bokslutskommuniké 2025 |
2025-10-21 | N/A | Kvartalsrapport 2025-Q3 |
2025-07-22 | N/A | Kvartalsrapport 2025-Q2 |
2025-04-29 | N/A | Kvartalsrapport 2025-Q1 |
2025-03-12 | N/A | Årsstämma |
2025-02-05 | N/A | Bokslutskommuniké 2024 |
2024-10-22 | - | Kvartalsrapport 2024-Q3 |
2024-07-23 | - | Kvartalsrapport 2024-Q2 |
2024-04-23 | - | Kvartalsrapport 2024-Q1 |
2024-03-13 | - | Årsstämma |
2024-03-13 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
2024-03-12 | - | Årsstämma |
2024-01-30 | - | Bokslutskommuniké 2023 |
2023-10-24 | - | Kvartalsrapport 2023-Q3 |
2023-07-25 | - | Kvartalsrapport 2023-Q2 |
2023-04-25 | - | Kvartalsrapport 2023-Q1 |
2023-03-13 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
2023-03-10 | - | Årsstämma |
2023-01-31 | - | Bokslutskommuniké 2022 |
2022-10-25 | - | Kvartalsrapport 2022-Q3 |
2022-07-21 | - | Kvartalsrapport 2022-Q2 |
2022-04-26 | - | Kvartalsrapport 2022-Q1 |
2022-03-09 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
2022-03-08 | - | Årsstämma |
2022-02-01 | - | Bokslutskommuniké 2021 |
2021-10-26 | - | Kvartalsrapport 2021-Q3 |
2021-07-22 | - | Kvartalsrapport 2021-Q2 |
2021-04-27 | - | Kvartalsrapport 2021-Q1 |
2021-03-09 | - | X-dag ordinarie utdelning EMBLA 0.00 DKK |
2021-03-08 | - | Årsstämma |
2021-02-02 | - | Bokslutskommuniké 2020 |
2020-10-27 | - | Kvartalsrapport 2020-Q3 |
2020-07-23 | - | Kvartalsrapport 2020-Q2 |
2020-04-30 | - | Kvartalsrapport 2020-Q1 |
2020-03-13 | - | X-dag ordinarie utdelning EMBLA 0.15 DKK |
2020-03-12 | - | Årsstämma |
2020-02-04 | - | Bokslutskommuniké 2019 |
2019-10-22 | - | Kvartalsrapport 2019-Q3 |
2019-07-25 | - | Kvartalsrapport 2019-Q2 |
2019-04-30 | - | Kvartalsrapport 2019-Q1 |
2019-03-08 | - | X-dag ordinarie utdelning EMBLA 0.14 DKK |
2019-03-07 | - | Årsstämma |
2019-02-05 | - | Bokslutskommuniké 2018 |
2018-10-24 | - | Kvartalsrapport 2018-Q3 |
2018-07-25 | - | Kvartalsrapport 2018-Q2 |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-03-09 | - | X-dag ordinarie utdelning EMBLA 0.13 DKK |
2018-03-08 | - | Årsstämma |
2018-02-05 | - | Bokslutskommuniké 2017 |
2017-10-24 | - | Kvartalsrapport 2017-Q3 |
2017-07-25 | - | Kvartalsrapport 2017-Q2 |
2017-04-27 | - | Kvartalsrapport 2017-Q1 |
2017-03-10 | - | X-dag ordinarie utdelning EMBLA 1.95 DKK |
2016-03-11 | - | X-dag ordinarie utdelning EMBLA 0.12 DKK |
2016-03-10 | - | Årsstämma |
2016-02-02 | - | Bokslutskommuniké 2015 |
2015-10-22 | - | Kvartalsrapport 2015-Q3 |
2015-07-23 | - | Kvartalsrapport 2015-Q2 |
2015-04-29 | - | Kvartalsrapport 2015-Q1 |
2015-03-12 | - | Årsstämma |
2015-02-05 | - | Bokslutskommuniké 2014 |
2014-10-24 | - | Analytiker möte 2014 |
2014-10-23 | - | Kvartalsrapport 2014-Q3 |
2014-07-25 | - | Analytiker möte 2014 |
2014-07-24 | - | Kvartalsrapport 2014-Q2 |
2014-04-30 | - | Analytiker möte 2014 |
2014-04-29 | - | Kvartalsrapport 2014-Q1 |
2014-03-14 | - | Årsstämma |
2014-02-05 | - | Bokslutskommuniké 2013 |
2013-10-24 | - | Analytiker möte 2013 |
2013-10-23 | - | Kvartalsrapport 2013-Q3 |
2013-07-24 | - | Kvartalsrapport 2013-Q2 |
2013-04-24 | - | Kvartalsrapport 2013-Q1 |
2013-03-15 | - | Årsstämma |
2013-02-06 | - | Bokslutskommuniké 2012 |
2012-11-28 | - | Kapitalmarknadsdag 2012 |
2012-11-27 | - | Kapitalmarknadsdag 2012 |
2012-10-24 | - | Analytiker möte 2012 |
2012-10-23 | - | Kvartalsrapport 2012-Q3 |
2012-07-25 | - | Kvartalsrapport 2012-Q2 |
2012-04-24 | - | Kvartalsrapport 2012-Q1 |
2012-03-16 | - | Årsstämma |
2012-02-08 | - | Bokslutskommuniké 2011 |
2011-10-27 | - | Kvartalsrapport 2011-Q3 |
2011-07-28 | - | Kvartalsrapport 2011-Q2 |
2011-03-04 | - | Årsstämma |
Beskrivning
Land | Island |
---|---|
Lista | Large Cap Copenhagen |
Sektor | Hälsovård |
Industri | Medicinteknik |
Announcement no. 48/2019
19 August 2019
Transactions in relation to share buyback program
On 14 May 2019, Össur hf. initiated a share buy-back program, see Company announcement no. 31/2019.
The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 31 December 2019. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.2% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.
The following transactions have been made under the program in week 14, the period 12 August 2019 – 16 August 2019:
Transactions | ||||||
Date | No. of shares | Avg. purchase price in DKK | Transaction value in DKK | |||
12 August 2019 | 9,032 | 45.53 | 411,185 | |||
13 August 2019 | 19,550 | 46.21 | 903,493 | |||
14 August 2019 | 20,000 | 45.99 | 919,832 | |||
15 August 2019 | 25,000 | 44.34 | 1,108,575 | |||
16 August 2019 | 20,150 | 45.23 | 911,376 | |||
Total | 93,732 | 45.39 | 4,254,461 |
Össur has acquired 1,455,998 shares under the program at the average price of DKK 41.16. Following the above transactions Össur’s holding of own shares is 2,342,266 corresponding to 0.55% of the Company’s total share capital.
The share buyback program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.
Further information
David Hreidarsson, Investor Relations, dohreidarsson@ossur.com, +354 515 1380
Össur press releases by e-mail
If you wish to receive Össur press releases by e-mail please register at http://www.ossur.com/investors
About Össur
Össur (NASDAQ OMX: OSSR) is a global leader in non-invasive orthopaedics that help people live a life without limitations. Its business is focused on improving people’s mobility through the delivery of innovative technologies within the fields of Prosthetics and Bracing & Supports. A recognized “Technology Pioneer,” Össur invests significantly in research and product development—its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur’s educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com
Attachment